天天舔天天爽_视频日韩_成人网线_天天草草草_免费一级在线观看_色综合色综合色综合色综合

NuVasive  
NuVasive是一個(gè)創(chuàng)新的全球醫(yī)療設(shè)備公司，改變脊柱外科微創(chuàng)破壞性脊柱外科產(chǎn)品 

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billionglobal spine market.

NuVasive offers a comprehensive spine portfolio of over 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS? platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company places a large focus on clinical research and support of theSociety of Lateral Access Surgery, or SOLAS?, to expand the body of clinical evidence in support of NuVasive'sminimally disruptive solutions and to drive adoption of its techniques. The Company's dedication to innovation continues to spawn game changing technology such as the PCM? motion preserving disc for the cervical spine, XLIF?Corpectomy for tumor and trauma, and Armada?, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 BillionStart-Up?; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation?, and Absolute Responsiveness?.